AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10102436
Drug: Praziquantel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (100 mg/kg in three divided doses at 2‐hour intervals)
Trial: 7598284
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg bolus followed by 20-min infusion at 9 micrograms.kg-1.min-1)
Trial: 2219614
Drug: Mesterolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesterolone (20 mg daily for 14 days)
Trial: 24894850
Drug: Observation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation with early salvage radiotherapy (SRT) triggered by PSA level >0.20 ng/mL
Trial: 20645280
Drug: Treatment satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment satisfaction data from four treatment arms
Trial: 16260426
Drug: Monascus purpureus
RxNorm normalized name: Monascus purpureus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monascus purpureus Went rice (600 mg)
Trial: 11185676
Drug: Azithromycin 1200
RxNorm normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1200 mg oral dose
Trial: 11185676
Drug: Nelfinavir 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 750 mg q8h for 11 days with concurrent azithromycin 1200 mg on Day 9
Trial: 1825266
Drug: Fenoterol, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol, 100 micrograms/dose
Trial: 1825266
Drug: Fenoterol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol, 200 micrograms/dose
Trial: 1825266
Drug: Fenoterol, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol, 50 micrograms and ipratropium, 20 micrograms/dose in a single inhaler (Berodual)
Trial: 1825266
Drug: Fenoterol, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol, 100 micrograms and ipratropium, 40 micrograms/dose in a single inhaler (Duovent)
Trial: 1825266
Drug: High-dose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose combination
Trial: 1825266
Drug: Low-dose fenoterol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fenoterol and low-dose combination
Trial: 29552984
Drug: Edoxaban plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban plus aspirin
Trial: 27846071
Drug: Detectable breastmilk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable breastmilk RNA (≥40 copies/mL)
Trial: 22782052
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide (Ca(OH)2) and 2% chlorhexidine gel (CHX)
Trial: 19475583
Drug: Antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications (specific medications not detailed)
Trial: 12163424
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus moderate-intensity coumarin (3-month regimen)
Trial: 3046350
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (5 mg/kg every eight hours) for five days
Trial: 17327249
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (including pelvic floor muscle training and exercise and bladder control strategies)
Trial: 17327249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravaginal continence pessary and behavioral therapy
Trial: 11943517
Drug: Transdermal nitroglycerine
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerine 5-mg/24-hour patch
Trial: 1100299
Drug: Sodium secobarbital
RxNorm normalized name: Secobarbital Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium secobarbital (150 mg/70 kg)
Trial: 1100299
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of marihuana and secobarbital
Trial: 6102180
Drug: Cefazolin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (3 doses of 1 g each)
Trial: 21175792
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with probiotic-containing yogurt (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium longum, and Streptococcus thermophilus)
Trial: 21175792
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy without yogurt (control group)
Trial: 21175792
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with probiotic-containing yogurt
Trial: 17361128
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading dose, 15 mg maintenance dose) with ketoconazole (400 mg/day)
Trial: 17361128
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) with ketoconazole (400 mg/day)
Trial: 17361128
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) without ketoconazole
Trial: 17361128
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading dose, 15 mg maintenance dose) without ketoconazole
Trial: 8144266
Drug: 0.85 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85 g/kg dose of alcohol
Trial: 26418666
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + L (scaling and root planing plus adjunctive laser therapy)
Trial: 26418666
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + L
Trial: 23223117
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg IV ketamine (group K)
Trial: 21669126
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon β‐1a (IM IFN‐β‐1a)
Trial: 19136898
Drug: Rapid discontinuation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid discontinuation of prednisone (RDP)
Trial: 16962524
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg granisetron (Group A, n=70)
Trial: 16962524
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (Group B, n=70)
Trial: 8766398
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) with piritramide (bolus 2.5 mg, blocking time 20 minutes, no basal infusion)
Trial: 8766398
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia with bupivacaine 0.5% and intravenous PCA (same parameters as group 1) plus continuous epidural infusion of bupivacaine 0.1875% at 8 ml/h
Trial: 7201271
Drug: Fentanyl, 8
RxNorm normalized name: FentaNYL, 800 mcg buccal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl, 8 micrograms/kg with thiopental, 3 mg/kg
Trial: 7201271
Drug: Thiopental, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental, 6 mg/kg alone
Trial: 29663701
Drug: RAL 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL 0.1% cream
Trial: 29663701
Drug: RAL 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL 0.05% cream
Trial: 26850746
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (∼1.8 g/day) for ∼14 days
Trial: 20403018
Drug: Alcoholic beverage
RxNorm normalized name: Alcoholic beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic beverage (mean = 0.12 g% breath alcohol concentration)
Trial: 18316629
Drug: Hyperinsulinemia (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemia (plasma insulin increased to 400 pmol/L)
Trial: 12610003
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg daily (Irb150)
Trial: 12610003
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg daily (Irb300)
Trial: 8602660
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg x kg‐1 cisatracurium
Trial: 8602660
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg x kg‐1 cisatracurium
Trial: 6461281
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (40 mcg from a metered dose inhaler)
Trial: 30640362
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg once weekly for 48 weeks
Trial: 22908773
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate and dry extract of Agropyrum repens (CalcoMEV) at the dose of 24 mEq of potassium citrate and 100 mg of dry extract of Agropyrum repens bis in die
Trial: 22908773
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate at a dose of 20 mEq ter in die
Trial: 17661767
Drug: Oral sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sotalol (80 mg twice daily) and magnesium supplementation
Trial: 1390141
Drug: 0.05% solution
RxNorm normalized name: Equate Nasal Spray 0.05% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% solution of a commercial dish-washing product (three times/day, for 15 min, at 37 degrees C) for 3 weeks
Trial: 31647496
Drug: Intravitreous ranibizumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous ranibizumab, 0.5 mg, at baseline and as frequently as every 4 weeks
Trial: 27362442
Drug: ACE (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE (2.3 g/day)
Trial: 26176940
Drug: Standard EC-MPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA (4.5 mg/kg/day for low risk DGF, 2.5 mg/kg/day for high risk DGF)
Trial: 26176940
Drug: Standard EC-MPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA
Trial: 23714268
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg three times per week for 3 months
Trial: 21621886
Drug: Low-volume enteral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume enteral supplement containing key nutrients
Trial: 21621886
Drug: Diluted standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted standard nutrition solution
Trial: 16824845
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus GPIIb/IIIa inhibitors
Trial: 10836008
Drug: High-dose IFN‐α(2b)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN‐α(2b)
Trial: 10836008
Drug: Lymphadenectomy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphadenectomy or adjuvant IFN‐α(2b) therapy
Trial: 9643529
Drug: GMDP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMDP solution (0.5-1.0 mg daily)
Trial: 9643529
Drug: GMDP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMDP solution (1.5 mg/kg daily)
Trial: 9643529
Drug: GMDP solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMDP solution
Trial: 7621303
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pravastatin 20mg/day and Nicotinic acid 1000mg/day)
Trial: 3258558
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human calcitonin-gene-related peptide (hCGRP) 2.5 micrograms
Trial: 3258558
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human calcitonin-gene-related peptide (hCGRP) 10 micrograms
Trial: 3258558
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human calcitonin-gene-related peptide (hCGRP) 25 micrograms
Trial: 31584311
Drug: Dried apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried apple (120 kcal serving, twice daily)
Trial: 31584311
Drug: Control snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control snack (muffin, 120 kcal serving, twice daily)
Trial: 24726378
Drug: Microfracture-based cartilage
RxNorm normalized name: SHARK CARTILAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfracture-based cartilage repair treatment
Trial: 24198887
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy (scaling & root planing) in Group B
Trial: 24198887
Drug: No periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No periodontal treatment in Group A
Trial: 27950663
Drug: EGF 50
RxNorm normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EGF 50 mug/ml
Trial: 10789889
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg) administered prior to both encoding and retrieval
Trial: 10789889
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered prior to both encoding and retrieval
Trial: 10789889
Drug: Alcohol administered
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administered prior to encoding and retrieval
Trial: 8918499
Drug: Breast-conservation treatment
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conservation treatment (lumpectomy) in node-negative trials
Trial: 8918499
Drug: Breast-conservation treatment
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conservation treatment (lumpectomy) in node-positive trials
Trial: 24271056
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (tamoxifen followed by exemestane)
Trial: 21055087
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole prophylaxis
Trial: 16266450
Drug: Prompt fibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt fibrinolytic therapy
Trial: 2324541
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccine (ProHibit)
Trial: 371021
Drug: Oxprenolol 160
RxNorm normalized name: oxprenolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 160 mg in a slow-release formulation with cyclopenthiazide 0.25 mg and potassium chloride 600 mg given once daily
Trial: 371021
Drug: Methyldopa 250
RxNorm normalized name: methyldopa 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa 250 mg 3 times daily
Trial: 23425607
Drug: MMRV(new WS)
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV(new WS) vaccine
Trial: 22211198
Drug: Radial shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shock wave therapy in addition to physical therapy
Trial: 12801243
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid (UA) 0.5 g in 250 ml of 0.1% lithium carbonate/4% dextrose vehicle
Trial: 11063279
Drug: Intensive multifactorial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE‐inhibitors, protocol‐driven tight control of blood glucose, blood pressure and cholesterol)
Trial: 11063279
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (according to current national guidelines)
Trial: 9115065
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg) for 45 days
Trial: 1492231
Drug: Dose-intensive chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensive chemotherapy regimens supported by GM-CSF
Trial: 3890909
Drug: Etomidate (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (continuous infusion increasing from 0.01 mg kg‐1 min‐1 to 0.05 mg kg‐1 min‐1 over 50 min)
Trial: 28699973
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group focusing on lifestyle changes, physical activities, and nutritional education, with activities occurring monthly in the school's multimedia room or sports court.
Trial: 23011712
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg; maximum dose, 20 mg)
Trial: 20212252
Drug: Continuous 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX)
Trial: 20212252
Drug: Intermittent 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent 6-mercaptopurine (100 mg/m(2)/d for 10 days, with 11 days resting) and MTX (200 mg/m(2) every 3 weeks)
Trial: 10609427
Drug: Offset control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Offset control over gas inhalation
Trial: 10609427
Drug: No offset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No offset control over gas inhalation
Trial: 7426219
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg kg‐1 i.v. (group I)
Trial: 7426219
Drug: Gallamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallamine 0.3 mg kg‐1 i.v. (group II)
Trial: 7426219
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg kg‐1 i.m. and gallamine 0.3 mg kg‐1 i.v. (group III)
Trial: 7426219
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg kg‐1 i.v. and gallamine 0.3 mg kg‐1 i.v. (group IV)
Trial: 26435849
Drug: Litramine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litramine (3 g/day)
Trial: 23768279
Drug: Visceral manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visceral manipulation (VM) added to standard physiotherapy treatment regimen.
Trial: 23768279
Drug: Standard physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physiotherapy treatment regimen (manual therapy, specific exercise, functional exercise prescription).
Trial: 21417617
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release liquid form of codeine (69.7 mg every 12 h)
Trial: 21417617
Drug: Codeine in
RxNorm normalized name: codeine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine in solution (23.2 mg every 4 h)
Trial: 18393643
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL prilocaine infiltration
Trial: 18393643
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL prilocaine infiltration
Trial: 12172339
Drug: Reboxetine 8
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 8 to 10 mg/day
Trial: 12172339
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 to 40 mg/day
Trial: 10692976
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) and 1000 mg calcium per day (n = 10)
Trial: 10692976
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg calcium per day (n = 14)
Trial: 10692976
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, n = 10)